NCT05578417View on ClinicalTrials.gov

A Study to Review the Treatment and Outcomes of Teenagers and Adults With Non-histaminergic Angioedema With Normal C1 Inhibitor in Canada

CompletedOBSERVATIONAL
Enrollment

60

Participants

Timeline

Start Date

June 15, 2023

Primary Completion Date

March 31, 2024

Study Completion Date

June 30, 2024

Conditions
Hereditary Angioedema (HAE)Angioedema
Interventions
OTHER

No Intervention

As this is an observational study, no intervention will be administered.

Trial Locations (6)

T2N 2T9

Alberta Health Services, Calgary

T6G 2B7

Alberta Health Services, Edmonton

V5Z 1H8

Vancouver Allergy Clinic, Vancouver

R3A 1R9

University of Manitoba, Winnipeg

L8S 4K1

Hamilton Health Science Corporation, Hamilton

G1V 4G2

CHU de Québec - Université Laval, Québec

Sponsors

Lead Sponsor

Takeda
All Listed Sponsors
lead

Takeda

INDUSTRY

NCT05578417 - A Study to Review the Treatment and Outcomes of Teenagers and Adults With Non-histaminergic Angioedema With Normal C1 Inhibitor in Canada | Biotech Hunter | Biotech Hunter